Image

Language, Speech and Motor Function in MCI Due to AD and Alzheimer's Disease

Language, Speech and Motor Function in MCI Due to AD and Alzheimer's Disease

Recruiting
All
Phase N/A

Powered by AI

Overview

The goal of this observational cross-sectional study is to explore the characteristics of language, speech, and motor function in persons with Mild Cognitive Impairment due to Alzheimer's disease ("MCI due to AD") and persons with mild and moderate Alzheimer's disease ("AD"). This study aims to:

  • Explore motor, speech, and language functions in MCI due to AD and mild and moderate AD.
  • Combine the characteristics of motor, language, and speech functions to gain more insight into the association of language, speech, and motor changes during MCI due to AD and mild and moderate AD.

Researchers will compare the outcomes to an age-matched control group without cognitive impairment.

Participants will undergo:

  • Two motor function tests to assess gait and hand grip strength.
  • Four language and speech function tests to assess spontaneous speech and verbal fluency..

Eligibility

Inclusion Criteria:

A subject with MCI with a likelihood of underlying AD pathophysiology must meet the following criteria:

  • Established diagnosis of MCI due to AD with a likelihood according to NIA-AA criteria (Albert et al., 2011).
  • A score of stage three on the Global Deterioration Scale (GDS) (Reisberg et al., 1982).

A subject with AD must meet the following criteria:

  • Established diagnosis of AD (amnestic or non-amnestic) or etiologically mixed presentation of AD according to DSM-5 (American Psychiatric Association, 2013) or NINCDS-ARDRA criteria (Jack et al., 2018; McKann et al., 2011).
  • The following scores on the Global Deterioration Scale (GDS): four for mild AD, five for moderate AD (Reisberg et al., 1982).

All subjects of the control group must meet the following criteria:

  • A score of stage one or two on the Global Deterioration Scale (GDS) (Reisberg et al., 1982).
  • They are age-matched with the MCI due to AD or AD patients included in the study.

All subjects must meet the following criteria:

  • First language is Dutch and/or Frisian.
  • Able to walk independently with or without walking aid.
  • Able to squeeze with each hand.

Exclusion Criteria:

A subject with MCI due to AD or AD who meets the following criteria will be excluded from participation in this study:

  • Having a neurological or neurodegenerative disease or disorder that may be contributing to cognitive impairment above and beyond that caused by AD or mixed AD; Down's syndrome, other subtypes of dementia, autism spectrum disorder.
  • Having an established diagnosis of a psychiatric disorder, e.g. schizophrenia, depression.

All subjects in the control group who meets following criteria will be excluded from participation in this study:

● Suffers from a neurological, neurodegenerative or psychiatric disease or disorder.

All subjects in any group who meet any of the following criteria will be excluded from participation in this study:

  • Hearing loss (with or without hearing aid) that affects communication.
  • Vision loss (with or without glasses or lenses) that affects communication.
  • History of language problems, speech problems or dyslexia.
  • Suffers from additional disorders or diseases which may limit gait, hand grip strength, language and/or speech.
  • Medication use that influence gait, hand grip strength, speech or language performance at time of testing.
  • Being terminally ill (i.e., life expectancy < 2 weeks according to the attending physician).

Study details
    Alzheimer's Disease
    MCI Due to AD
    Dementia Alzheimers

NCT06508268

Hanze University of Applied Sciences Groningen

14 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.